Skip to main content

. 1987 Nov;80(11):708–709. doi: 10.1177/014107688708001118

Drug overdose--a hidden hazard of obesity.

J Cox ¹, N Penn ¹, M Masood ¹, A K Hancock ¹, D Parker ¹

PMCID: PMC1291097 PMID: 3694619

708

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Benjamin R. S., Riggs C. E., Jr, Bachur N. R. Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):592–600. doi: 10.1002/cpt1973144part1592. [DOI] [PubMed] [Google Scholar]
Benjamin R. S., Wiernik P. H., Bachur N. R. Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer. 1974 Jan;33(1):19–27. doi: 10.1002/1097-0142(197401)33:1<19::aid-cncr2820330107>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
Brenner D. E., Wiernik P. H., Wesley M., Bachur N. R. Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia. Cancer. 1984 Mar 1;53(5):1042–1048. doi: 10.1002/1097-0142(19840301)53:5<1042::aid-cncr2820530505>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
Lee Y. T., Chan K. K., Harris P. A., Cohen J. L. Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration. Cancer. 1980 May 1;45(9):2231–2239. doi: 10.1002/1097-0142(19800501)45:9<2231::aid-cncr2820450902>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
Von Hoff D. D., Layard M. W., Basa P., Davis H. L., Jr, Von Hoff A. L., Rozencweig M., Muggia F. M. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979 Nov;91(5):710–717. doi: 10.7326/0003-4819-91-5-710. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES